1708113-43-2

Basic information

• Product Name: ACY-1083
• CAS NO: 1708113-43-2
• Molecular Weight: 348.352
• Mol File: 1708113-43-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ACY-1083(CAS DataBase Reference)
• NIST Chemistry Reference: ACY-1083(1708113-43-2)
• EPA Substance Registry System: ACY-1083(1708113-43-2)

Safety Data

• Hazardous Substances Data: 1708113-43-2(Hazardous Substances Data)

Upstream product

• 95261-39-5 4-amino-4-phenylcyclohexan-1-one 
• 861857-71-8 2-methyl-propane-2-sulfinic acid (1,4-dioxa-spiro[4.5]dec-8-ylidene)-amide 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Relevant articles and documents

Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy

Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.

TREATMENT OF POLYCYSTIC DISEASES WITH AN HDAC6 INHIBITOR

An HDAC6-specific inhibitor (i.e., a compound of Formula I or II) is shown to reduce the pathogenesis associated with polycystic disease. Administration of an HDAC6-specific inhibitor attenuated many of the symptoms characteristic of polycystic liver disease including cyst formation, cyst growth and cholangiocyte proliferation. Treatment with a HDAC6-specific inhibitor also increased the amount of bile duct acetylated tubulin and β-catenin phosphorylation and/or acetylation while reducing bile duct β-catenin synthesis. These results demonstrate that HDAC6 is overexpressed in cystic cholangiocytes and that its pharmacological inhibition reduces cholangiocyte proliferation and cyst growth.